



Thermo Scientific  
Early Prenatal Care

# Pre-eclampsia screening

## in 1<sup>st</sup> trimester of pregnancy

Early screening for pre-eclampsia enables optimal patient care

- Placental Growth Factor (PIGF) screening: high detection rates and possible intervention
- High sensitivity PIGF measurement with Thermo Scientific B·R·A·H·M·S PIGF plus KRYPTOR

**Thermo**  
SCIENTIFIC


# Early screening – early intervention

## Pre-eclampsia screening in 1<sup>st</sup> trimester for optimal patient care

### Serum PIGF determination in combination with other factors allows early prediction of pre-eclampsia

Pre-eclampsia is a leading cause of maternal morbidity and mortality. Early identification of women at high risk for pre-eclampsia allows intensified maternal and fetal monitoring which offers the potential of reducing an adverse outcome for mother and child. First trimester screening of Placental Growth Factor (PIGF) allows early detection of women at risk for early-onset pre-eclampsia before any clinical symptoms occur.

**With the new high sensitivity assay Thermo Scientific™ B-R-A-H-M-S™ PIGF plus KRYPTOR™ maternal serum PIGF levels can be detected already at weeks 11-13 of gestation.**



### Early-onset pre-eclampsia causes severe complications

Pre-eclampsia is defined as new onset of hypertension (systolic blood pressure  $\geq 140$  mmHg or diastolic blood pressure  $\geq 90$  mmHg on two occasions) and proteinuria ( $\geq 300$  mg/day) after 20 weeks of gestation.<sup>1</sup> The degree of adverse maternal and fetal consequences is inversely related to the gestational age at onset.<sup>2</sup>

Therefore, pre-eclampsia can be classified as<sup>2</sup>

- Early-onset at 20-34 weeks (severe pre-eclampsia)
- Intermediate-onset at 34-37 weeks (medium pre-eclampsia)
- Late-onset after 37 weeks (moderate pre-eclampsia)




## Low-dose aspirin can reduce the risk of pre-eclampsia

A recent meta-analysis has shown that the application of low-dose aspirin (<150 mg/day) started before week 16 of gestation caused a significant reduction in pre-eclampsia and intrauterine fetal growth restriction (IUGR) compared to control, while aspirin started after 16 weeks of gestation did not.<sup>4,5</sup>

Literature suggests that the use of low-dose aspirin during pregnancy is safe with regard to congenital anomalies and fetal, neonatal, and maternal cardiovascular physiologic state and hemostasis.<sup>6</sup>

First onset of clinical symptoms of pre-eclampsia (hypertension, proteinuria)



**Figure 1** First clinical symptoms of pre-eclampsia are observed >20 weeks of gestation. The gestational age at onset correlates with the occurrence of maternal and fetal consequences.<sup>2</sup>

# Pre-eclampsia: a leading cause of maternal morbidity and mortality

## Severe complications for the mother

With an incidence between 2-8% pre-eclampsia is a frequent pregnancy disorder<sup>7</sup>, affecting more than 4.1 million women per year worldwide.<sup>8</sup>


The severe pre-eclampsia variant HELLP syndrome (**H**emolysis, **E**levated **L**iver enzymes, **L**ow **P**latelets) occurs in about 20% of the affected women and is defined by an additional affection of the liver and the coagulation system, resulting in symptoms such as abdominal pain, hemorrhage, placental abruption, hepatic infarction and rupture, intra-abdominal bleeding and edema. Eclampsia is the final and most feared stage of the disease, associated with severe tonic-clonic seizures and coma as well as brain injury, cerebral edema and stroke.<sup>9</sup>

**HELLP syndrome and eclampsia account for more than 50 000 maternal deaths each year.<sup>7</sup>**

## Severe complications for the fetus

Due to an insufficient supply of oxygen and nutrients, pre-eclampsia also causes severe complications for the fetus, such as prematurity, IGUR, bronchopulmonary dysplasia and sometimes even death.<sup>9</sup>

**About 15-20% of preterm deliveries are due to pre-eclampsia.<sup>9</sup>**



**Figure 2** Causes of maternal death worldwide (Total is more than 100% due to rounding)<sup>8</sup>



## Long-term complications for the women

Pre-eclampsia is responsible for long-term complications later in life. Large retrospective epidemiological studies have shown that women with a previous pre-eclampsia have a 3-4 times higher risk for cardiovascular disorders later in life than non pre-eclamptic women. The risk is even higher (4-8 fold) if the onset of pre-eclampsia was before 34 weeks of gestation or pre-eclampsia was combined with a preterm birth.<sup>9</sup>


**The risk of death from cardiovascular and cerebrovascular disease is 50% greater in women with a history of pre-eclampsia.<sup>9</sup>**

The underlying mechanism that accounts for the elevated risk is not yet well understood, but it was shown that endothelial dysfunction persists for many years in women with a former pre-eclampsia episode.<sup>9</sup>

## Risk factors

The risk factors for pre-eclampsia are varied and unique to this condition and include<sup>9</sup>

- Maternal and paternal family history
- Previous pregnancy with pre-eclampsia
- Multiple pregnancy (triplets > twins)
- Maternal Age (>40 years)
- Body Mass Index (BMI >30)
- Pre-existing hypertension, Diabetes mellitus or renal disease
- Systemic inflammation
- Ethnical origin



**Figure 3** Odds ratio and 95% confidence interval (CI) of risk factors for development of pre-eclampsia (PE)<sup>10</sup>




# Imbalance of pro- and antiangiogenic proteins

## A key factor for developing pre-eclampsia

### Normal pregnancy

Placenta and developing fetus are provided with sufficient maternal oxygen and nutrients<sup>11</sup>


- Fetal cytotrophoblast cells invade maternal uterine wall (into smooth muscle and endothelial layer)
- Maternal spiral arteries are remodeled into large vessels with high capacity and low resistance



### Pre-eclamptic pregnancy

Inadequate circulation between placenta and uterus<sup>11</sup>

- Invasion of cytotrophoblasts is incomplete, they can only be found in superficial layers of decidua
- Maternal spiral arteries fail to be invaded/ remodeled, resulting in vessels with a decreased capacity and increased resistance








## Maternal PIGF serum concentration is decreased in pre-eclampsia

Pre-eclampsia is a disease that begins in the placenta and ends at the maternal endothelium.<sup>9</sup> The cause of pre-eclampsia is still not well understood, but the placenta has been identified as the central organ in pathogenesis.<sup>9</sup> The inadequate blood supply explains the consequences for the fetus in pre-eclampsia.

Recent studies suggest that an imbalance of proangiogenic and antiangiogenic proteins accounts for many maternal complications with respect to pre-eclampsia. Antiangiogenic factors such as sFlt-1 (soluble FMS-like Tyrosine Kinase) and sEng (soluble Endoglin) are released by an abnormal placenta into the blood, where they antagonize the effects of proangiogenic factors such as VEGF (Vascular Endothelial Growth Factors) and PIGF (Placental Growth Factor).<sup>9</sup>

### Vasodilation



### Vasoconstriction

- Y Flt-1
- VEGF
- PIGF
- ⌋ sFlt-1

**Figure 4** In pre-eclampsia, sFlt-1 is released by an abnormal placenta and concentrations are increased, whereas concentration of free PIGF is decreased. This imbalance of circulating factors is assumed to be responsible for an increased maternal vascular inflammation, finally resulting in endothelial dysfunction and hence clinical signs of pre-eclampsia.<sup>12</sup>



# 1<sup>st</sup> trimester PIGF measurement


identifies women at risk for pre-eclampsia before clinical symptoms appear

## PIGF – a proangiogenic factor

Placental Growth Factor (PIGF) belongs to the Vascular Endothelial Growth Factors (VEGF) family, which are promoting proliferation and survival of endothelial cells and inducing vascular permeability. During pregnancy, the placenta releases high amounts of PIGF. PIGF binds to the Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) also known as FMS-like Tyrosine Kinase-1 (Flt-1).

## Low PIGF levels indicate increased risk for pre-eclampsia

In normal pregnancy, the concentration of PIGF increases progressively from week 12, reaching a peak during weeks 29-32 and declining thereafter. Compared to controls, the PIGF concentrations of those women who later develop pre-eclampsia are significantly lower, and can be measured as early as week 12.<sup>13</sup>



### No. of specimens

Controls	20	44	56	9	72	21	70	21
Before pre-eclampsia	21	43	56	6	75	23	57	19
>5 weeks before pre-eclampsia	21	43	56	6	71	19	8	–
During pre-eclampsia	–	–	–	–	–	2	14	26

**Figure 5** Mean PIGF concentrations of healthy women and those women who later developed pre-eclampsia<sup>13</sup>





## High detection rate of pre-eclampsia by combining maternal characteristics with a high sensitivity PIGF assay

Using the traditional screening method, based on maternal history only, the detection rate for women who are at risk for developing pre-eclampsia is about 30%. Detection rates become more accurate when maternal characteristics are combined with PIGF measurement as well as other factors such as serum PAPP-A (both measured in weeks 11-13), mean arterial pressure (MAP), and uterine artery Doppler (uA-PI), resulting in a detection rate of >90% for cases of early pre-eclampsia for a fixed false positive rate of 5% before any clinical symptoms appear.<sup>2</sup>

**An effective prediction of pre-eclampsia can be achieved already at weeks 11-13 of gestation.<sup>3</sup>**

	DR at 5% FPR	History	MAP	uA-PI	PAPP-A	PIGF
DR	Detection rate					
FPR	False positive rate	●		●		
History	Maternal history	●			●	
MAP	Mean arterial blood pressure	●				●
uA-PI	Uterine artery pulsatility index	●		●	●	
		●	●	●	●	●
		●	●	●	●	●
		●	●	●	●	●
		●	●	●	●	●
		●	●	●	●	●

**Table 1** Different studies with resulting detection rates by using different screening methods<sup>14</sup>

**With a high sensitivity assay  
PIGF levels can already be detected  
in weeks 11-13 of gestation.**




# Thermo Scientific B·R·A·H·M·S PIGF plus KRYPTOR

## High sensitivity and exceptional precision

B·R·A·H·M·S PIGF plus KRYPTOR is an automated immunofluorescent assay for the quantitative determination of the concentration of human PIGF (Placental Growth Factor) in human serum. The assay is specific for the measurement of human free PIGF-1.

- 75 determinations per kit
- 29 min incubation time
- FAS: 6.7 pg/mL
- Single-point calibration
- Monoparametric control kit, 3 levels
- Wide measuring range: 3.6-7 000 pg/mL
- Excellent precision

With a detection limit of less than 4 pg/mL B·R·A·H·M·S PIGF plus KRYPTOR provides the high sensitivity needed for measuring PIGF levels in the first trimester of pregnancy.





## Thermo Scientific B·R·A·H·M·S PIGF plus KRYPTOR Early pre-eclampsia screening provides optimal patient care



Exceptionally precise, fast and easy

Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS

**17 Years Reliable Results**  
**17 Years Confident Decisions**

- All KRYPTOR platforms FMF approved
- In routine use by FMF since 1999
- Excellent precision and proven median stability
- OSCAR compatible



## Thermo Scientific B·R·A·H·M·S Biomarkers Prenatal Screening Markers on KRYPTOR Systems

• B·R·A·H·M·S <b>AFP</b> KRYPTOR	Art. no.: 816.075
• B·R·A·H·M·S <b>Free <math>\beta</math>hCG</b> KRYPTOR	Art. no.: 809.075
• B·R·A·H·M·S <b>hCG+<math>\beta</math></b> KRYPTOR	Art. no.: 841.050
• B·R·A·H·M·S <b>Inhibin A</b> KRYPTOR	(under development)
• B·R·A·H·M·S <b>PAPP-A</b> KRYPTOR	Art. no.: 866.075
• B·R·A·H·M·S <b>PIGF plus</b> KRYPTOR*	Art. no.: 859.075
• B·R·A·H·M·S <b>sFit-1</b> KRYPTOR*	Art. no.: 845.075
• B·R·A·H·M·S <b>uE3</b> KRYPTOR**	Art. no.: 803.075
• B·R·A·H·M·S <b>Fast Screen pre I plus Software</b>	Art. no.: 105750

\* Available on KRYPTOR compact PLUS

\*\* Available on KRYPTOR and KRYPTOR compact PLUS

### References

1. Definition of the American College of Obstetrics and Gynaecology
2. Akolekar R et al. Prenat Diagn 2011; 31: 66-74
3. Poon LCY et al. Hypertension 2009; 53: 812-818
4. Bujold E et al. J Obstet Gynaecol 2010; 116: 402-14
5. Bujold E et al. J Obstet Gynaecol can 2009; 31: 818-26
6. Dekker GA et al. Am J Obstet Gynaecol 1993; 168(1 Pt 1): 214-27
7. Ghulmiyyah L and Sibai B. Seminars in Perinatology 2012; 36: 56-59
8. The World Health Report 2005; p62
9. Powe CE et al. Circulation 2011; 123: 2856-69
10. Nicolaides KH. Fetal Diagn Ther 2011; 29(3): 183-96
11. Lam C et al. Hypertension 2005; 46: 1077-85
12. Yuan HT et al. Curr Top Dev Biol 2005; 71: 297-312
13. Levine RJ et al. N Engl J Med 2004; 350: 672-83
14. Costa FS et al. Rev Bras Ginecol Obstet 2011; 33 (11): 367-75

[thermoscientific.com/brahms](http://thermoscientific.com/brahms)

© 2016 Thermo Fisher Scientific Inc. All rights reserved.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR is a trademark of CIS bio international, licensed for use by B·R·A·H·M·S, a part of Thermo Fisher Scientific.

Thermo Fisher Scientific products are distributed worldwide; not all intended uses and applications mentioned in this printing are registered in every country.

### Clinical Diagnostics

Thermo Fisher Scientific  
B·R·A·H·M·S GmbH  
Neuendorfstr. 25  
16761 Hennigsdorf  
Germany

+49 (0)3302 883 0  
+49 (0)3302 883 100 fax  
[info.brahms@thermofisher.com](mailto:info.brahms@thermofisher.com)

[www.thermoscientific.com/brahms](http://www.thermoscientific.com/brahms)  
[www.thermoscientific.com/copeptin](http://www.thermoscientific.com/copeptin)  
[www.thermoscientific.com/proadrenomedullin](http://www.thermoscientific.com/proadrenomedullin)  
[www.thermoscientific.com/procalcitonin](http://www.thermoscientific.com/procalcitonin)  
[www.thermoscientific.com/kryptor](http://www.thermoscientific.com/kryptor)

**Thermo**  
SCIENTIFIC

A Thermo Fisher Scientific Brand